View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease ...

Prime Medicine to Host Virtual KOL Event to Showcase Wilson’s Disease Strategy -- Webcast event to begin at 8:00am ET on Wednesday, November 12, 2025 -- CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it will host a virtual event on Wednesday, November 12, 2025, to discuss its liver disease franchise and strategy, with a focus on Wilson’s Disease. Prime Medicine remains on track to file an investigational new d...

 PRESS RELEASE

Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIR...

Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting HOUSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced it will present at the being held October 30-31, 2025 at the MD Anderson Cancer Center Spain Foundation in Madrid, Spain. Details of the presentation are as follows: Title: L-Annamycin - Non-Cardi...

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
 PRESS RELEASE

Moleculin Expands Global IP Portfolio with New Australian Patent for A...

Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin HOUSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced that the Australian Patent Office (IP Australia) has granted Patent No. 2024203598 titled, “PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE,” with claims covering certain preliposomal Annamycin lyophilizates with improved stability and high purity, w...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: October 25, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Moleculin Announces New Investigator-Initiated Study of Annamycin for ...

Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer Atlantic Health, a leading provider of health care based in New Jersey, to conduct the investigator-initiated Phase 1B/2 study Preclinical studies indicate Annamycin targets key factors in pancreatic cancer HOUSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced it is working with Atlant...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: October 18, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

David Nierengarten ... (+4)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
  • Yun Zhong

KOL Call Today @ 1PM ET: Just Breathe: Genetic Medicines in AATD

Dr. Hogarth completed his residency in internal medicine (1998-2001) and his fellowship in pulmonary and critical care medicine (2001-2004) before joining the University of Chicago faculty as an Assistant Professor of Medicine (2004-2014). He was later promoted to Associate Professor of Medicine (2

David Nierengarten ... (+4)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
  • Yun Zhong

KOL Call On Wednesday: Just Breathe: Genetic Medicines in AATD

Dr. Hogarth completed his residency in internal medicine (1998-2001) and his fellowship in pulmonary and critical care medicine (2001-2004) before joining the University of Chicago faculty as an Assistant Professor of Medicine (2004-2014). He was later promoted to Associate Professor of Medicine (2

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: October 11, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

THOR Industries Announces Regular Quarterly Dividend

THOR Industries Announces Regular Quarterly Dividend ELKHART, Ind., Oct. 08, 2025 (GLOBE NEWSWIRE) -- THOR Industries, Inc. (NYSE: THO) today announced that its Board of Directors approved, at its October 8, 2025, meeting, the payment of a regular quarterly cash dividend of $0.52 per share. The regular cash dividend is payable on November 6, 2025, to shareholders of record at the close of business on October 23, 2025. About THOR Industries, Inc. THOR is the sole owner of operating companies which, combined, represent the world's largest manufacturer of recreational vehicles. For more ...

David Nierengarten ... (+4)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
  • Yun Zhong
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: October 7, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Prime Medicine to Participate in Upcoming Investor Conferences

Prime Medicine to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in two upcoming conferences: H.C. Wainwright Genetic Medicines Virtual Conference 2025: Fireside chat will be available to view on demand beginning Tuesday, October 14, 2025. Company management will host virtual 1x1 meetings on Wednesday, October 15, 2025.Chardan’s 9th ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: October 4, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch